🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.810
+0.130 (7.74%)
At close: Nov 20, 2026, 4:00 PM EST
1.870
+0.060 (3.31%)
After-hours: Nov 20, 2026, 7:59 PM EST

Pyxis Oncology Statistics

Total Valuation

Pyxis Oncology has a market cap or net worth of $216.49 million. The enterprise value is $178.32 million.

Market Cap216.49M
Enterprise Value 178.32M

Important Dates

The last earnings date was Thursday, November 5, 2026, before market open.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

Pyxis Oncology has 119.61 million shares outstanding. The number of shares has increased by 10.82% in one year.

Current Share Class 119.61M
Shares Outstanding 119.61M
Shares Change (YoY) +10.82%
Shares Change (QoQ) +30.50%
Owned by Insiders (%) 4.20%
Owned by Institutions (%) 25.16%
Float 58.87M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 19.61
Forward PS 11,136.33
PB Ratio 3.66
P/TBV Ratio 5.24
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 16.15
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.96, with a Debt / Equity ratio of 0.42.

Current Ratio 2.96
Quick Ratio 2.79
Debt / Equity 0.42
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -157.51% and return on invested capital (ROIC) is -74.58%.

Return on Equity (ROE) -157.51%
Return on Assets (ROA) -59.94%
Return on Invested Capital (ROIC) -74.58%
Return on Capital Employed (ROCE) -153.90%
Weighted Average Cost of Capital (WACC) 11.10%
Revenue Per Employee $197,107
Profits Per Employee -$1.55M
Employee Count56
Asset Turnover 0.12
Inventory Turnover n/a

Taxes

In the past 12 months, Pyxis Oncology has paid $1.10 million in taxes.

Income Tax 1.10M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -60.39% in the last 52 weeks. The beta is 1.41, so Pyxis Oncology's price volatility has been higher than the market average.

Beta (5Y) 1.41
52-Week Price Change -60.39%
50-Day Moving Average 2.13
200-Day Moving Average 2.16
Relative Strength Index (RSI) 51.91
Average Volume (20 Days) 976,492

Short Selling Information

The latest short interest is 4.53 million, so 3.78% of the outstanding shares have been sold short.

Short Interest 4.53M
Short Previous Month 4.35M
Short % of Shares Out 3.78%
Short % of Float 7.69%
Short Ratio (days to cover) 3.37

Income Statement

In the last 12 months, Pyxis Oncology had revenue of $11.04 million and -$86.71 million in losses. Loss per share was -$1.27.

Revenue11.04M
Gross Profit 8.65M
Operating Income -87.46M
Pretax Income -85.61M
Net Income -86.71M
EBITDA -83.50M
EBIT -87.46M
Loss Per Share -$1.27
Full Income Statement

Balance Sheet

The company has $55.57 million in cash and $17.40 million in debt, with a net cash position of $38.17 million or $0.32 per share.

Cash & Cash Equivalents 55.57M
Total Debt 17.40M
Net Cash 38.17M
Net Cash Per Share $0.32
Equity (Book Value) 41.32M
Book Value Per Share 0.49
Working Capital 39.19M
Full Balance Sheet

Cash Flow

Operating Cash Flow -70.93M
Capital Expenditures n/a
Depreciation & Amortization 3.96M
Net Borrowing n/a
Free Cash Flow -70.93M
FCF Per Share -$0.59
Full Cash Flow Statement

Margins

Gross Margin 78.37%
Operating Margin -792.32%
Pretax Margin -775.55%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Pyxis Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -10.82%
Shareholder Yield -10.82%
Earnings Yield -70.07%
FCF Yield -32.76%

Analyst Forecast

The average price target for Pyxis Oncology is $8.22, which is 354.25% higher than the current price. The consensus rating is "Strong Buy".

Price Target $8.22
Price Target Difference 354.25%
Analyst Consensus Strong Buy
Analyst Count 9
Revenue Growth Forecast (3Y) -11.83%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Pyxis Oncology has an Altman Z-Score of -9.41 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -9.41
Piotroski F-Score 2